On September 26, 2022 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies, reported that it will present at the Cantor Fitzgerald Oncology, Hematology & HemOnc Conference, which is being held on September 28th at the Lotte New York Palace Hotel. Actinium’s Chief Medical Officer, Dr. Avinash Desai, will be participating in a panel titled, "Addressing Challenges in Cell Therapy and Transplant" (Press release, Actinium Pharmaceuticals, SEP 26, 2022, View Source [SID1234621407]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, members of the executive team will be available for one-on-one meetings with conference attendees. Those interested in scheduling a meeting may do so by contacting their Cantor Fitzgerald representative.